DDInter1014 DDInter1376
Lacosamide is an antiepileptic drug used to treat seizures. As a chiral functionalized amino acid, it works by blocking slowly inactivating components of voltage-gated sodium currents. Lacosamide exhibits a stereoselective mode of interaction with sodium channels. Lacosamide was first approved by the European Commission in August 2008 and was later approved by the FDA in October 2008. It was granted approval by Health Canada in September 2010.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Lacosamide {u} (Compound) resembles {v} (Compound) Lisdexamfetamine
Lacosamide {u} (Compound) resembles {v} (Compound) Bethanidine
Lacosamide {u} (Compound) treats {v} (Disease) epilepsy syndrome
Lacosamide {u} (Compound) binds {v} (Gene) SCN10A
Lacosamide {u} (Compound) is included by {v} (Pharmacologic Class) Decreased Central Nervous System Disorganized Electrical Activity
Lacosamide {u} (Compound) causes {v} (Side Effect) Liver function test abnormal
Lacosamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lidocaine
Lacosamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fingolimod
Lacosamide {u} may lead to a major life threatening interaction when taken with {v} Dolasetron
Lacosamide (Compound) resembles Lisdexamfetamine (Compound)
Lacosamide (Compound) resembles Bethanidine (Compound)
Lacosamide (Compound) treats epilepsy syndrome (Disease)
Lacosamide (Compound) binds SCN10A (Gene)
Lacosamide (Compound) is included by Decreased Central Nervous System Disorganized Electrical Activity (Pharmacologic Class)
Lacosamide (Compound) causes Liver function test abnormal (Side Effect)
Lacosamide may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine
Lacosamide may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod
Lacosamide may lead to a major life threatening interaction when taken with Dolasetron